AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024

Core Insights - AbCellera will present four posters at the AACR Annual Meeting 2024, showcasing advancements in its T-cell engager programs and platform aimed at improving cancer treatment efficacy and safety [1][2]. Group 1: T-cell Engager Platform - The T-cell engager platform is designed to enhance therapeutic opportunities by generating molecules that target solid tumors and challenging targets like peptide-MHCs [1][2]. - AbCellera's T-cell engagers utilize bispecific antibodies that simultaneously bind T cells and tumor targets, facilitating the immune system's ability to eliminate cancer cells [3]. Group 2: Poster Presentations - The first poster will focus on functional and specific T-cell engagers against a peptide-MHC tumor target, scheduled for April 8, 2024 [2]. - The second poster will present diverse CD28-binding antibodies for optimizing T-cell engagers, also on April 8, 2024 [2]. - The third poster will discuss design considerations for bispecific T-cell engagers, set for April 8, 2024 [2]. - The fourth poster will cover the development of PSMA x CD3 T-cell engagers using an integrated approach, scheduled for April 9, 2024 [2]. Group 3: Company Overview - AbCellera is focused on revolutionizing antibody drug discovery to expedite the delivery of better medicines to patients [4][5]. - The company integrates expert teams, technology, and data science to enhance the efficiency of antibody-based medicine development across various therapeutic areas [4][5].